M. Riedel et al., QUALITY-OF-LIFE IN PATIENTS WITH ADDISONS-DISEASE - EFFECTS OF DIFFERENT CORTISOL REPLACEMENT MODES, Experimental and clinical endocrinology, 101(2), 1993, pp. 106-111
This study compares the impact of different modes of cortisol replacem
ent therapy on the health perception and general well-being in patient
s with primary adrenocortical failure. 14 adults (8 female, 6 male) wi
th Addison's disease on chronic cortisol replacement participated in t
he study. In a randomized double-blind cross-over design, all patients
were treated with 3 modes of cortisol replacement for one week each (
mode I: 20 mg hydrocortison (HC) at 0700 h and 10 mg HC at 1900 h; mod
e II: 30 mg HC at 0700 h and placebo at 1900 h; mode III: placebo at 0
700 h and 30 mg HC at 1900 h). Following the third week, the replaceme
nt modes were repeated in a different random order. For quality-of-lif
e assessment the patients completed three different questionnaires (Ad
dison-questionnaire, Basler Befindlichkeits-Skala, Beschwerde-Liste) a
nd were interviewed about their general contentment at the last day of
each treatment week. General well-being in terms of subjective conten
tment was best established during mode I (in 64% of patients) and less
often stated with mode II (in 29%) and III (in 14%) (p < 0.05 mode I
vs III). With the twice-daily replacement (mode I), sum scores of all
questionnaires were changed towards improvement compared to both once-
daily regimens (p < 0.05 vs mode II and III), but did not reach normal
values of healthy subjects. Differences between mode II and III were
insignificant. We conclude that quality of life in Addison patients is
mainly influenced by the mode of cortisol replacement therapy. Althou
gh physiological conditions are not reestablished, the twice-daily med
ication exert better results in terms of general well-being and conten
tment than once-daily application modes.